1. Home
  2. NAK vs PCRX Comparison

NAK vs PCRX Comparison

Compare NAK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$2.33

Market Cap

1.2B

ML Signal

HOLD

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.88

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
PCRX
Founded
1983
2006
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
2002
2010

Fundamental Metrics

Financial Performance
Metric
NAK
PCRX
Price
$2.33
$22.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$2.50
$30.25
AVG Volume (30 Days)
6.8M
439.6K
Earning Date
05-15-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
107.44
EPS
N/A
0.07
Revenue
N/A
$541,533,000.00
Revenue This Year
N/A
$6.78
Revenue Next Year
N/A
$8.54
P/E Ratio
N/A
$333.71
Revenue Growth
N/A
26.04
52 Week Low
$0.73
$18.80
52 Week High
$2.98
$27.64

Technical Indicators

Market Signals
Indicator
NAK
PCRX
Relative Strength Index (RSI) 62.58 44.44
Support Level $1.85 $22.06
Resistance Level $2.44 $24.20
Average True Range (ATR) 0.15 1.00
MACD 0.01 0.01
Stochastic Oscillator 78.63 29.38

Price Performance

Historical Comparison
NAK
PCRX

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: